THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0

Historical Holders from Q4 2016 to Q3 2022

Type / Class
Debt / NOTE 3.250%11/0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 across Reporting Periods

Period Principal Value Change Price (% of par) Investors
2022 Q3 $0 $0 -$208,840,000 0
2022 Q2 $194,748,463 $208,840,000 -$11,244,822 92.75% 14
2022 Q1 $213,885,735 $228,859,000 +$9,277,508 95.0% 19
2021 Q4 $203,479,076 $221,077,000 -$8,799,217 96.61% 19
2021 Q3 $214,232,388 $199,159,544 +$1,523,738 92.68% 22
2021 Q2 $210,113,838 $200,080,896 -$8,472,347 95.24% 22
2021 Q1 $218,794,473 $223,386,639 -$11,047,671 102.01% 21
2020 Q4 $229,815,000 $217,617,000 +$3,131,762 94.65% 19
2020 Q3 $234,838,000 $207,543,000 -$2,883,104 88.28% 23
2020 Q2 $232,315,000 $226,055,274 +$25,304,734 97.17% 26
2020 Q1 $205,849,000 $201,108,200 -$3,822,747 96.54% 29
2019 Q4 $236,117,000 $241,820,000 -$420,323 103.64% 24
2019 Q3 $235,617,000 $218,670,000 +$11,381,315 92.48% 25
2019 Q2 $223,351,500 $193,184,303 -$12,104,761 86.5% 25
2019 Q1 $235,732,000 $229,563,000 -$768,451 97.26% 21
2018 Q4 $235,832,000 $242,738,000 -$3,101,615 102.92% 18
2018 Q3 $223,483,000 $263,688,000 -$5,951,946 118.25% 19
2018 Q2 $223,708,000 $221,274,000 +$773,286 99.05% 20
2018 Q1 $222,846,000 $226,059,000 -$734,954 101.49% 19
2017 Q4 $223,540,000 $245,223,000 +$11,226,159 109.64% 18
2017 Q3 $213,294,000 $262,094,000 -$665,818 122.69% 17
2017 Q2 $212,644,000 $287,330,000 -$3,293,717 135.04% 21
2017 Q1 $218,124,000 $276,121,000 +$4,871,300 126.63% 19
2016 Q4 $215,334,000 $246,874,000 +$246,874,000 114.8% 20